Relevant to this educational activity, James F. Howard, Jr., MD, has financial relationships with ineligible companies. Dr. Howard also intends to discuss the off-label use of a commercial product or device and has agreed to clearly identify any such use to learners.

Des Moines University Medicine and Health Sciences (DMU) is committed to ensuring that accredited continuing education serves the needs of patients and the public. Learners must receive accurate, balanced, and scientifically justified recommendations and be able to trust that accredited continuing education supports safe, effective, cost-effective, and compassionate care based on best practices and evidence.

Prior to the educational activity, DMU implemented the following strategies to mitigate Dr. Howard’s relevant financial relationships and ensure the education is fair, balanced, and free from commercial bias:

  1. Mitigated all relevant financial relationships through peer review by individuals without relevant financial relationships or through attestation to adherence to evidence-based guidelines for clinical recommendations.
  2. Reviewed Dr. Howard’s presentation materials and any associated handouts, case studies, and educational materials for commercial bias.
  3. Required the use of generic names whenever possible and the avoidance of promotional language or product endorsement.
  4. Ensured that any discussion of investigational or off-label uses is clearly identified as such.
  5. Disclosed Dr. Howard’s relevant financial relationships to learners prior to the educational activity, along with the mitigation measures implemented by DMU.

If you have any concerns or questions regarding Dr. Howard's presentation or disclosures, please email Dr. Vanessa Gray, Director of the DMU CME Program.

  • AbbVie Inc.
    • Self-managed stock shareholder
    • The financial relationship has not ended.
  • Ad Scientiam
    • Grants or Research Support
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Alexion AstraZeneca Rare Disease
    • Grants or Research Support
    • Consultant Advisory Board Member
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Amgen (Horizon Therapeutics plc, Viela Bio)
    • Consultant Advisory Board Member
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Argenx
    • Grants or Research Support
    • Consultant Advisory Board Member
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Biohaven Ltd.
    • Consultant Advisory Board Member
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Bristol Meyer Squibb
    • Self-managed stock shareholder
    • The financial relationship has ended.
  • Cartesian Therapeutics
    • Grants or Research Support
    • Consultant 
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Curie.bio
    • Consultant Scientific Advisor
    • The financial relationship has ended.
  • Flerie AB (formerly Toleranzia AB)
    • Consultant Advisory Board Member
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • GlaxoSmithKline
    • Self-managed stock shareholder
    • The financial relationship has not ended.
  • Hansa Biopharma
    • Consultant Scientific Advisor
    • The financial relationship has ended.
  • Japan Tobacco Company
    • Consultant Scientific Advisor
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Johnson & Johnson
    • Self-managed stock shareholder
    • The financial relationship has not ended.
  • Kyverna Therapeutics
    • Consultant Scientific Advisor
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • F. Hoffmann-LaRoche Ltd
    • Consultant Scientific Advisor
    • The financial relationship has ended, and it is relevant to the content of the education activity.
  • Merck EMD Serono
    • Grants or Research Support
    • Consultant Advisory Board
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • NMD Pharma
    • Grants or Research Support
    • Consultant Advisory Board
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Novartis
    • Consultant Advisory Board
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Pfizer
    • Self-managed stock shareholder
    • The financial relationship has not ended.
  • Regeneron Pharmaceuticals
    • Consultant Advisory Board
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Seismic Therapeutics
    • Consultant Scientific Advisor
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • TG Therapeutics
    • Consultant Scientific Advisor
    • The financial relationship has ended, and it is relevant to the content of the education activity.
  • UCB Biosciences
    • Grants or Research Support
    • Consultant Advisory Board Member
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Vor Biopharma
    • Grants or Research Support
    • Consultant Scientific Advisor
    • The financial relationship has not ended, and it is relevant to the content of the education activity.
  • Vertex
    • Consultant Scientific Advisor
    • The financial relationship has not ended, and it is relevant to the content of the education activity.